Abstract
A number of concerns were voiced in 2006 regarding the safety of the use of long-acting beta-agonists (LABAs) for treatment of asthma. These concerns included whether use of this class of drug increases the risk for hospitalization, near death, or death due to asthma, whether the increased risk was greater in African Americans, and whether individuals who are homozygous for arginine at the 16th codon of the beta2-adrenergic receptor have a poorer response or even deteriorate when prescribed LABAs. Subsequent studies have addressed each of these concerns. It is hoped that the consistently reassuring data that have been generated during the last 3 years will reduce the concerns among physicians, patients, and regulatory authorities regarding the safety of combination LABA and inhaled corticosteroid use in patients with asthma and allow the proper use of this valuable combination treatment for appropriate patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
